Abstract

Fusions in the ROS1 proto-oncogene are among the best treatable genetic aberrations in Non-small cell lung cancer (NSCLC). Besides the occurrence of solvent-front mutations (SFM) in acquired resistance to targeted therapy, little is known about small-scale ROS1 aberrations. We comprehensively analyzed clinical and molecular characteristics of ROS1 mutations in NSCLC patients without activating ROS1 fusions or SFMs.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call